Pioglitazone in Clinical Practice: Where Are We Now?

Pioglitazone, a thiazolidinedione, improves insulin sensitivity and thus reduces blood glucose. Clinical trials have suggested potential cardiovascular outcome benefits in association with pioglitazone; however, safety concerns are mounting, with recent data suggesting a link between pioglitazone an...

Descripción completa

Detalles Bibliográficos
Autores principales: Govindan, Joytish, Evans, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508118/
https://www.ncbi.nlm.nih.gov/pubmed/22373598
http://dx.doi.org/10.1007/s13300-012-0001-z
_version_ 1782251182386839552
author Govindan, Joytish
Evans, Marc
author_facet Govindan, Joytish
Evans, Marc
author_sort Govindan, Joytish
collection PubMed
description Pioglitazone, a thiazolidinedione, improves insulin sensitivity and thus reduces blood glucose. Clinical trials have suggested potential cardiovascular outcome benefits in association with pioglitazone; however, safety concerns are mounting, with recent data suggesting a link between pioglitazone and an increased risk of bladder cancer. There is thus a growing focus on the risk–benefit profile of this agent and hence its potential role in the blood glucose-lowering treatment algorithm for people with type 2 diabetes. There are clear potential outcome benefits associated with pioglitazone. In this review, the authors focus on putting the true risk–benefit profile of pioglitazone into context based on critical appraisal of the currently available evidence.
format Online
Article
Text
id pubmed-3508118
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer Healthcare Communications
record_format MEDLINE/PubMed
spelling pubmed-35081182012-11-28 Pioglitazone in Clinical Practice: Where Are We Now? Govindan, Joytish Evans, Marc Diabetes Ther Review Pioglitazone, a thiazolidinedione, improves insulin sensitivity and thus reduces blood glucose. Clinical trials have suggested potential cardiovascular outcome benefits in association with pioglitazone; however, safety concerns are mounting, with recent data suggesting a link between pioglitazone and an increased risk of bladder cancer. There is thus a growing focus on the risk–benefit profile of this agent and hence its potential role in the blood glucose-lowering treatment algorithm for people with type 2 diabetes. There are clear potential outcome benefits associated with pioglitazone. In this review, the authors focus on putting the true risk–benefit profile of pioglitazone into context based on critical appraisal of the currently available evidence. Springer Healthcare Communications 2012-02-29 2012-12 /pmc/articles/PMC3508118/ /pubmed/22373598 http://dx.doi.org/10.1007/s13300-012-0001-z Text en © The Author(s) 2012 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Govindan, Joytish
Evans, Marc
Pioglitazone in Clinical Practice: Where Are We Now?
title Pioglitazone in Clinical Practice: Where Are We Now?
title_full Pioglitazone in Clinical Practice: Where Are We Now?
title_fullStr Pioglitazone in Clinical Practice: Where Are We Now?
title_full_unstemmed Pioglitazone in Clinical Practice: Where Are We Now?
title_short Pioglitazone in Clinical Practice: Where Are We Now?
title_sort pioglitazone in clinical practice: where are we now?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508118/
https://www.ncbi.nlm.nih.gov/pubmed/22373598
http://dx.doi.org/10.1007/s13300-012-0001-z
work_keys_str_mv AT govindanjoytish pioglitazoneinclinicalpracticewherearewenow
AT evansmarc pioglitazoneinclinicalpracticewherearewenow